How effective could laser-based approaches be in assisting dendritic cell immunotherapy?

Immunotherapy

Volumn 4, Issue 10, 2012, Pages 983-985

  Chen, Xinyuan ^a   Wu, Mei X ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

adjuvant; cancer vaccine; dendritic cell; immunotherapy; intradermal injection; laser; local environment; maturation; migration; preconditioning

Indexed keywords

CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MONOCLONAL ANTIBODY; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR AGONIST; TUMOR CELL VACCINE;

CASTRATION RESISTANT PROSTATE CANCER; CELL MATURATION; CELL MIGRATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNOTHERAPY; LOW LEVEL LASER THERAPY; LYMPH NODE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; LASER THERAPY; LASERS; PORTRAITS AS TOPIC;

EID: 84869151634     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.101     Document Type: Review

References (20)

1. Pinzon-Charry A, Maxwell T, Lopez JA. Dendritic cell dysfunction in cancer: A mechanism for immunosuppression. Immunol. Cell. Biol. 83, 451-461 (2005).
2. Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2, 52-58 (1996).
3. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps. Nat. Rev. Cancer 11, 805-812 (2011).
4. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castrationresistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010).
5. Sabado RL, Bhardwaj N. Directing dendritic cell immunotherapy towards successful cancer treatment. Immunotherapy 2, 37-56 (2010).
6. Rosenblatt J, Glotzbecker B, Mills H et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J. Immunother. 34, 409-418 (2011).
7. Ribas A, Comin-Anduix B, Chmielowski B et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin. Cancer Res. 15, 6267-6276 (2009).
8. Jacobs JF, Punt CJ, Lesterhuis WJ et al. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: A Phase I/II study in metastatic melanoma patients. Clin. Cancer Res. 16, 5067-5078 (2010).
9. Chen X, Zeng Q, Wu MX. Improved efficacy of dendritic cell-based immunotherapy by cutaneous laser illumination. Clin. Cancer Res. 18, 2240-2249 (2012).
10. Chen X, Kim P, Farinelli B et al. A novel laser vaccine adjuvant increases the motility of antigen presenting cells. PLoS ONE 5, e13776 (2010).
11. Liu L, Zhong Q, Tian T, Dubin K, Athale SK, Kupper TS. Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nat. Med. 16, 224-227 (2010).
12. Key ME, Hanna MG Jr. Mechanism of action of BCG-tumor cell vaccines in the generation of systemic tumor immunity. II. Influence of the local inflammatory response on immune reactivity. J. Natl Cancer Inst. 67, 863-869 (1981).
13. MartIn-Fontecha A, Sebastiani S, Hopken UE et al. Regulation of dendritic cell migration to the draining lymph node: Impact on T lymphocyte traffic and priming. J. Exp. Med. 198, 615-621 (2003).
14. Tripp CH, Ebner S, Ratzinger G, Romani N, Stoitzner P. Conditioning of the injection site with CpG enhances the migration of adoptively transferred dendritic cells and endogenous CD8+ T-cell responses. J. Immunother. 33, 115-125 (2010).
15. Chen X, Wu MX. Laser vaccine adjuvant for cutaneous immunization. Expert Rev. Vaccines 10, 1397-1403 (2011).
16. Adema GJ, de Vries IJ, Punt CJ, Figdor CG. Migration of dendritic cell based cancer vaccines: In vivo veritas? Curr. Opin Immunol. 17, 170-174 (2005).
17. Mosca PJ, Lyerly HK, Clay TM, Morse MA, Lyerly HK. Dendritic cell vaccines. Front. Biosci. 12, 4050-4060 (2007).
18. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F. Kinetics of dendritic cell activation: Impact on priming of TH1, TH2 and nonpolarized T cells. Nat. Immunol. 1, 311-316 (2000).
19. Mullins DW, Sheasley SL, Ream RM, Bullock TN, Fu YX, Engelhard VH. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J. Exp. Med. 198, 1023-1034 (2003).
20. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG. Dendritic cells injected via different routes induce immunity in cancer patients. J. Immunol. 166, 4254-4259 (2001).